Get the tools used by (smart)2 investors.

Predicted EV / EBITDA Exit Multiple (FY+5) for AstraZeneca

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

ZEG: AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso...

- EUR
Price
EUR
Fair Value
Upside
- - -
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on AstraZeneca's Predicted EV / EBITDA Exit Multiple (FY+5):

ZEGHLTH.GB0QAH0Q1N0R340QLRGSK0.0x4.0x8.0x12.0x

Performance Summary
  • AstraZeneca's predicted ev / ebitda exit multiple (fy+5) is 10.7x

How does AstraZeneca's Predicted EV / EBITDA Exit Multiple (FY+5) benchmark against competitors?

Hide this widget

We've identified the following companies as similar to AstraZeneca because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Metric Usage: Predicted EV / EBITDA Exit Multiple (FY+5)

Hide this widget
prediction_exit_ev_to_ebitda_multiple_5y
Slug
number
Datatype
text
Format
current
Default Period
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Predicted EV / EBITDA Exit Multiple (FY+5) in the predictions category include:

  • Predicted EV / EBITDA Exit Multiple (FY+5) - Our estimate of the fair value EV / EBITDA Exit Multiple (FY+5) for a company.
  • Predicted Market Cap / LTM AFFO - Our estimate of the fair value Market Cap / LTM AFFO for a REIT.
  • Fair Value Label - Fair Value label assigned based on the percentage upside when compared to internal fair value estimate. Value is one of UNAVAILABLE, BARGAIN, UNDERVALUED, FAIR, OVERVALUED, or EXPENSIVE
  • Fair Value Downside - The percentage decrease (if positive) or increase (if negative) that our models estimate over the current stock price.
View Full List

Search for metric or datapoint

Predicted EV / EBITDA Exit Multiple (FY+5)

Our estimate of the fair value EV / EBITDA Exit Multiple (FY+5) for a company.

Definition of Predicted EV / EBITDA Exit Multiple (FY+5)

Hide this widget
Our estimate of the fair value EV / EBITDA Exit Multiple (FY+5) for a company.

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-2.3x7.7x17.7x36.2x050100150

The chart above depicts the distribution of predicted ev / ebitda exit multiple (fy+5) for companies operating in the Healthcare sector in the Developed economic region. Over 1,275 companies were considered in this analysis, and 1,228 had meaningful values. The average predicted ev / ebitda exit multiple (fy+5) of companies in the sector is 6.7x with a standard deviation of 6.1x.

AstraZeneca's Predicted EV / EBITDA Exit Multiple (FY+5) of 10.7x ranks in the 80.5% percentile for the sector. The following table provides additional summary stats:

Predicted EV / EBITDA Exit Multiple (FY+5) In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents1,280
Included Constituents1,228
Min-2.8x
Max35.6x
Median5.7x
Mean6.7x
Standard Deviation6.1x

You can find companies with similar predicted ev / ebitda exit multiple (fy+5) using this stock screener.

All rights reserved. Terms Of Use